Amphista Therapeutics is a fast-growing Cambridge-based biotech and the leading European Targeted Protein Degradation (TPD) company. Our unique scientific approach to TPD, one of the hottest areas in modern drug discovery, gives us a range of advantages over other therapeutic strategies. In addition to an oversubscribed $53M funding round in 2021. We were delighted to recently announce two separate collaboration deals with Bristol Myers Squibb and Merck Healthcare which will allow us to grow and advance our therapeutic portfolio even faster. Initially founded from the laboratory of Professor Alessio Ciulli (University of Dundee) our team comprises both academic and drug discovery pioneers of the TPD field and a growing R&D team focused on advancing a portfolio of medicines to the clinic using our proprietary next generation TPD technologies.
As a key part of Amphista R&D leadership, you’ll work closely with the VP of Drug Discovery as well as chemistry, biology, pharmacology and development leaders as well as senior leadership including CSO, CEO and others. This is an exciting opportunity to join a fast growing and dynamic company operating at the cutting edge of one of the most transformational recent developments in drug discovery strategies to develop first in class and best in class medicines.
The successful candidate will lead and contribute to Amphista’s protein degrader drug discovery and development programs and have a significant impact on the success of the company and R&D strategy.
Leading and working within project and functional teams, you’ll help drive project advancement and decisions from the lead identification and optimisation phases through to candidate selection and development across the Amphista portfolio.
Education / Experience:
Your application was submitted successfully.